Salarius Pharmaceuticals Regains Nasdaq Compliance for Merger

Salarius Pharmaceuticals ( (SLRX) ) just unveiled an update.

On October 10, 2025, Salarius Pharmaceuticals regained compliance with Nasdaq’s Equity Standard, a crucial step in its planned merger with Decoy Therapeutics. The merger aims to leverage Decoy’s peptide conjugate therapeutics and Salarius’ assets to target unmet needs in respiratory diseases and GI oncology. The combined company will be led by Decoy’s leadership team and expects to advance its lead asset to an IND application with the FDA within the next year.

Spark’s Take on SLRX Stock

According to Spark, TipRanks’ AI Analyst, SLRX is a Underperform.

Salarius Pharmaceuticals exhibits significant financial instability, characterized by declining revenues and persistent losses, which severely impacts its stock score. Technically, the stock is on a bearish trend, trading below major moving averages, with negative momentum indicators. The valuation is further weakened by a negative P/E ratio and absence of dividend, making it unattractive to value or income investors. Overall, the stock is highly risky and requires cautious consideration.

To see Spark’s full report on SLRX stock, click here.

More about Salarius Pharmaceuticals

Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients with limited options. Its product portfolio includes seclidemstat, under study for hematologic cancers, and SP-3164, an oral small molecule protein degrader. Salarius has received financial backing from organizations like the National Pediatric Cancer Foundation and the Cancer Prevention and Research Institute of Texas.

Average Trading Volume: 318,699

Technical Sentiment Signal: Strong Sell

Current Market Cap: $3.71M

Find detailed analytics on SLRX stock on TipRanks’ Stock Analysis page.